Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026994 | 0.95 | MAPT (0.43) | MAPTNPC1RAB9AKDM4EMETAP1 | |
| SCHEMBL2227750 | 0.79 | TSHR (0.48) | MAPTGPR35ALDH1A1CYP19A1CYP3A4 | |
| SCHEMBL21624988 | 0.77 | NPC1 (0.39) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL308655 | 0.76 | TSHR (0.44) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL9598969 | 0.75 | KDM4E (0.42) | MAPTNPC1RAB9AKDM4EMETAP1 | |
| SCHEMBL308765 | 0.75 | KDM4E (0.42) | MAPTNPC1RAB9AKDM4EMETAP1 | |
| SCHEMBL29851568 | 0.74 | ABL1 (0.57) | MAPTNPC1RAB9AKDM4EMETAP1 | |
| SCHEMBL7032457 | 0.74 | ABL1 (0.57) | MAPTNPC1RAB9AKDM4EMETAP1 | |
| SCHEMBL30305663 | 0.72 | KDM4E (0.50) | MAPTNPC1RAB9AKDM4EMETAP1 | |
| SCHEMBL1367753 | 0.72 | KDM4E (0.50) | MAPTNPC1RAB9AKDM4EMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10219730-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20160296147-A1 | Redox Polymers | THERASENSE, INC. | 2016-10-13 | — | — | US | disclosed |
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| US-9320467-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9324504-B2 | Organic metal dye, and photoelectric element and dye-sensitized solar cell using the organic metal dye | SFC CO., LTD. (KR) | 2016-04-26 | — | — | US | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-20140364710-A1 | Redox Polymers | THERASENSE, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828204-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| EP-1230248-B1 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | THERASENSE INC (US) | 2007-06-06 | — | — | EP | disclosed |
| US-6605200-B1 | Charge transfer compounds comprising polymers such as polyvinylpyridine and/or copolymers coupled to osmium compounds, used as biosensors in redox systems | THERASENSE, INC. | 2003-08-12 | — | — | US | disclosed |
| EP-1230248-A2 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | Therasense, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001036660-A2 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | THERASENSE, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-0243450-B1 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES | FMC Corporation (US) | 1993-04-28 | — | — | EP | disclosed |
| EP-0243450-A4 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES. | FMC CORP (US) | 1989-09-11 | — | — | EP | disclosed |
| US-4808722-A | PLANT GROWTH REGULATORS | FMC CORPORATION (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0243450-A1 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES. | FMC CORP (US) | 1987-11-04 | — | — | EP | disclosed |
| WO-1987002665-A1 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES | FMC CORPORATION (US) | 1987-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | PARK7, HSPA9, NLN | MAPT 123/4885NPC1 311/4885RAB9A 1201/4885 |
| US-10219730-B2 | Redox polymers | PPOX, OTC, ME3 | MAPT 3737/4885NPC1 4855/4885RAB9A 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.